相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The endocannabinoid system and cardiometabolic risk
Paul E. Szmitko et al.
ATHEROSCLEROSIS (2008)
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease -: The STRADIVARIUS randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old
Kenneth F. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia
Isabel Matias et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Fatima Teixeira-Clerc et al.
NATURE MEDICINE (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
SM Grundy et al.
CIRCULATION (2005)
Activation of the peripheral endocannabinoid system in human obesity
S Engeli et al.
DIABETES (2005)
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance
O Jbilo et al.
FASEB JOURNAL (2005)
Cannabinoid-based drugs as anti-inflammatory therapeutics
TW Klein
NATURE REVIEWS IMMUNOLOGY (2005)
Endocannabinoid control of food intake and energy balance
V Di Marzo et al.
NATURE NEUROSCIENCE (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
S Steffens et al.
NATURE (2005)
Molecular Biology of the Enzymes that Degrade Endocannabinoids
Robyn A. Puffenbarger
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2005)
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults
S Malik et al.
CIRCULATION (2004)
Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome
CB Jones et al.
CARDIOVASCULAR RESEARCH (2003)
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
ML Casanova et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
The macrophage foam cell as a target for therapeutic intervention
AC Li et al.
NATURE MEDICINE (2002)
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors
AC Howlett et al.
PHARMACOLOGICAL REVIEWS (2002)
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes
S Sugiyama et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
A classification of unstable angina revisited
CW Hamm et al.
CIRCULATION (2000)
分享论文
